Table 4. Sales volumes of Critically Important Antimicrobials of Highest Priority.
| CEP3 | CEP4 | MCL | PMY | QUI | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| year | volume [t] | change [%] | volume [t] | change [%] | volume [t] | change [%] | volume [t] | change [%] | volume [t] | change [%] |
| 2011 | 2,057 | 1,427 | 173,137 | 127,339 | 8,247 | |||||
| 2012 | 2,346 | +14,04 | 1,399 | -1,95 | 144,676 | -16,44 | 123,478 | -3,03 | 10,382 | +25,89 |
| 2013 | 2,320 | -1,10 | 1,363 | -2,58 | 126,046 | -12,88 | 124,701 | +0,99 | 12,125 | +16,78 |
| 2014 | 2,315 | -0,20 | 1,401 | +2,78 | 108,667 | -13,79 | 106,657 | -14,47 | 12,346 | +1,82 |
| 2015 | 2,280 | -1,54 | 1,325 | -5,39 | 52,463 | -51,72 | 81,825 | -23,28 | 10,555 | -14,50 |
| 2016 | 2,301 | +0,94 | 1,122 | -15,32 | 54,663 | +4,19 | 68,909 | -15,78 | 9,339 | -11,52 |
| 2017 | 2,335 | +1,49 | 1,062 | -5,39 | 54,723 | +0,11 | 73,566 | +6,76 | 9,905 | +6,06 |
| 2018 | 1,256 | -46,24 | 0,474 | -55,37 | 58,677 | +7,23 | 73,594 | +0,04 | 7,717 | -22,09 |
| change | -0,801 | -38,96 | -0,953 | -66,79 | -114,460 | -66,11 | -53,745 | -42,21 | -0,530 | -6,43 |
Sales volumes are expressed in tons of active ingredient [t]. Changes in percent refer to the previous year. CEP3: cephalosporins of the 3rd generation, CEP4: cephalosporins of the 4th generation, MCL: macrolides, PMY: polymyxins, QUI: quinolones